Biomolecules 2013, 3(3), 435-448; doi:10.3390/biom3030435
Article

Altered Sphingolipid Metabolism in Patients with Metastatic Pancreatic Cancer

1 Pennsylvania state Hershey cancer institute, Hershey, PA17033, USA 2 Department of pharmacology, Hershey, PA17033, USA 3 Department of gastrointestinal medical oncology, the University of Texas MD Anderson cancer center, Houston, TX77030, USA 4 Department of orthopedics Pennsylvania state college of medicine, 500 University Drive, Hershey, PA 17033, USA
* Author to whom correspondence should be addressed.
Received: 23 May 2013; in revised form: 10 July 2013 / Accepted: 24 July 2013 / Published: 25 July 2013
(This article belongs to the Special Issue Sphingolipids and Bioactive Lipids)
PDF Full-text Download PDF Full-Text [520 KB, uploaded 25 July 2013 15:50 CEST]
Abstract: Although numerous genetic mutations and amplifications have been identified in pancreatic cancer, much of the molecular pathogenesis of the disease remains undefined. While proteomic and transcriptomic analyses have been utilized to probe and characterize pancreatic tumors, lipidomic analyses have not been applied to identify perturbations in pancreatic cancer patient samples. Thus, we utilized a mass spectrometry-based lipidomic approach, focused towards the sphingolipid class of lipids, to quantify changes in human pancreatic cancer tumor and plasma specimens. Subgroup analysis revealed that patients with positive lymph node metastasis have a markedly higher level of ceramide species (C16:0 and C24:1) in their tumor specimens compared to pancreatic cancer patients without nodal disease or to patients with pancreatitis. Also of interest, ceramide metabolites, including phosphorylated (sphingosine- and sphinganine-1-phosphate) and glycosylated (cerebroside) species were elevated in the plasma, but not the pancreas, of pancreatic cancer patients with nodal disease. Analysis of plasma level of cytokine and growth factors revealed that IL-6, IL-8, CCL11 (eotaxin), EGF and IP10 (interferon inducible protein 10, CXCL10) were elevated in patients with positive lymph nodes metastasis, but that only IP10 and EGF directly correlated with several sphingolipid changes. Taken together, these data indicate that sphingolipid metabolism is altered in human pancreatic cancer and associated with advanced disease. Assessing plasma and/or tissue sphingolipids could potentially risk stratify patients in the clinical setting.
Keywords: sphingolipids; pancreatic cancer; ceramide; lipidomics; CXCL10

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Jiang, Y.; DiVittore, N.A.; Young, M.M.; Jia, Z.; Xie, K.; Ritty, T.M.; Kester, M.; Fox, T.E. Altered Sphingolipid Metabolism in Patients with Metastatic Pancreatic Cancer. Biomolecules 2013, 3, 435-448.

AMA Style

Jiang Y, DiVittore NA, Young MM, Jia Z, Xie K, Ritty TM, Kester M, Fox TE. Altered Sphingolipid Metabolism in Patients with Metastatic Pancreatic Cancer. Biomolecules. 2013; 3(3):435-448.

Chicago/Turabian Style

Jiang, Yixing; DiVittore, Nicole A.; Young, Megan M.; Jia, Zhiliang; Xie, Keping; Ritty, Timothy M.; Kester, Mark; Fox, Todd E. 2013. "Altered Sphingolipid Metabolism in Patients with Metastatic Pancreatic Cancer." Biomolecules 3, no. 3: 435-448.

Biomolecules EISSN 2218-273X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert